Korean J Med.  2025 Apr;100(2):75-80. 10.3904/kjm.2025.100.2.75.

Treatment Approaches for Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia

• Koh JS
• Song IC

• KMID: 2566387
• DOI: http://doi.org/10.3904/kjm.2025.100.2.75

Abstract

Philadelphia chromosome-like acute lymphoblastic leukemia (ALL) is a group of diseases that possess similar gene expression patterns to those of Philadelphia chromosome-positive ALL, but lack the BCR-ABL1 gene rearrangement and exhibit diverse genetic characteristics. These cases are associated with a poorer prognosis than that of other B-cell ALL cases and require novel therapeutic approaches. Philadelphia chromosome-like ALL can be categorized into ABL-activated, Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway-altered, and other subtypes based on genetic alterations. For the ABL-activated subtype, treatment with ABL-directed tyrosine kinase inhibitors may improve outcomes, whereas JAK-directed tyrosine kinase inhibitors have been proposed as a combination therapy for patients with JAK-STAT pathway mutations. In this review, we discuss treatment approaches for each subtype of Philadelphia chromosome-like ALL.

Keyword

Philadelphia chromosome-like; Precursor cell lymphoblastic leukemia-lymphoma; Tyrosine kinase inhibitors; 필라델피아 염색체-유사; 급성 림프모구백혈병; 타이로신키나제억제제